Imatinib and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Imatinib
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed imatinib (Gleevec) and cariprazine (Vraylar) together. Your body clears cariprazine using a liver enzyme called CYP3A4. Imatinib slows that enzyme down, so cariprazine and its long-lasting active form can build up higher than usual in your body.
That extra buildup can mean stronger side effects, like restlessness, sleepiness, dizziness, muscle stiffness, or unusual movements. The good news is this is very manageable. Your care team will usually lower your cariprazine dose or space it out (for example, taking it every other day) and watch how you feel. Please don't change anything on your own. Just talk with your doctor or pharmacist so they can tailor your dose.
Effect: Imatinib, a moderate CYP3A4 inhibitor, decreases metabolism of cariprazine (a CYP3A4 substrate), increasing exposure to cariprazine and its active metabolite didesmethylcariprazine (DDCAR). Neither is a prodrug requiring 3A4 activation, so effect and toxicity risk rise. DDCAR's long half-life means accumulation persists.
- Direction: increased cariprazine/DDCAR exposure (AUC)
- Severity/evidence: major; probable
- Management (per labeling): Initiating cariprazine on a moderate inhibitor: 1.5 mg every other day. If already stable on 1.5 or 3 mg daily, reduce to 1.5 mg every other day; on 4.5 or 6 mg daily, reduce to 1.5 mg once daily.
- On inhibitor discontinuation, cariprazine dose may need to be increased per response/tolerability.
- Monitor for EPS, akathisia, sedation.
What happens
Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure
Interaction Deep Dive
Giving cariprazine (a CYP3A4 substrate) together with a moderate CYP3A4 inhibitor can raise the levels of both cariprazine and its active metabolite, didesmethylcariprazine. If cariprazine therapy is being started in a patient already receiving a moderate CYP3A4 inhibitor (for schizophrenia or bipolar mania), begin with 1.5 mg orally every other day; this may be raised to 1.5 mg orally every other day, if warranted and guided by clinical response and tolerability. For patients on a moderate CYP3A4 inhibitor being treated for bipolar depression or receiving adjunctive therapy for MDD, the dose is 1.5 mg orally every other day. When a moderate CYP3A4 inhibitor is added for someone already stabilized on cariprazine, dosage should be modified as follows: for patients currently taking 1.5 or 3 mg once daily, reduce cariprazine to 1.5 mg orally every other day when the moderate inhibitor is started; for patients currently taking cariprazine 4.5 or 6 mg once daily, change to 1.5 mg orally once daily when the moderate inhibitor is started. Should the moderate CYP3A4 inhibitor later be stopped, the cariprazine dose may require an increase according to clinical response and tolerability1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
Keep taking both medications as prescribed unless your care team tells you otherwise. This combination is manageable with dose tailoring and monitoring.
- Your team may lower your cariprazine dose or move it to every-other-day dosing, following the manufacturer's recommendations, depending on your current dose and why you take it.
- They may watch you more closely for side effects like restlessness, involuntary movements, stiffness, or drowsiness.
- If imatinib is later stopped, your cariprazine dose may need to be raised again.
Tell your pharmacist or prescriber that you take both, and report any new or worsening side effects.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction investigations, giving cariprazine 1.5 mg/day together with erythromycin (a moderate CYP3A4 inhibitor) 500 mg twice daily for 21 days led to an increase in cariprazine AUC (0 to 24 hours) and Cmax of roughly 50% 1. In one study that enrolled only White males taking cariprazine 1.5 mg/day and erythromycin 500 mg twice daily (n=40), AUCs rose by 38% (cariprazine), 11% (desmethylcariprazine, an active metabolite), and 60% (didesmethylcariprazine, an active metabolite), and Cmax by 34%, 16%, and 62%, respectively. Tmax was not altered by coadministration with erythromycin 2.
Common questions
Can I take Imatinib and Cariprazine together?
Imatinib can raise cariprazine levels and side effect risk by blocking its breakdown, so your cariprazine dose will likely be lowered and you'll be watched more closely. Don't adjust anything yourself, talk with your doctor or pharmacist. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Imatinib and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Imatinib and Cariprazine interaction managed?
Keep taking both medications as prescribed unless your care team tells you otherwise. This combination is manageable with dose tailoring and monitoring. Your team may lower your cariprazine dose or move it to every-other-day dosing, following the manufacturer's recommendations, depending on your current dose and why you take it. They may watch you more closely for side effects like restlessness, i… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Imatinib or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
- Szabo M, Hujber Z, Harsanyi J, et al: Coadministration of cariprazine with a moderate CYP3A4 inhibitor in patients with schizophrenia: implications for dose adjustment and safety monitoring. Clin Pharmacokinet 2024; 63(10):1501-1510. PubMed
Keep reading about Imatinib
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist